The Role of MEK5 in Melatonin-induced Osteoblast and Osteoclast Differentiation

MEK5 在褪黑激素诱导的成骨细胞和破骨细胞分化中的作用

基本信息

  • 批准号:
    9098099
  • 负责人:
  • 金额:
    $ 36.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-07-01 至 2020-06-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Our long-term goal is to develop novel therapies to improve bone formation and increase bone density in women and men with osteopenia or osteoporosis. Melatonin is a novel alternative to current treatments because it possesses multiple bone-protective actions by working through a stimulation of osteoblasts, an inhibition of osteoclasts and possibly through its free-radical scavenging properties to protect bone cells against excessive bone resorption. It is expected that long-term use of melatonin in people will prevent osteopenia and osteoporosis and reduce bone fractures through its effects on both osteoblasts and osteoclasts. The objective is to clarify the mechanism(s) underlying melatonin's effects on osteoblasts and osteoclasts in rodent bone and in vitro using a novel co-culture system consisting of human mesenchymal stem cells (hMSCs) and human peripheral blood monocytes (hPBMCs). The project goal is to identify the role of MEK5 and MEK1/2 on regulating melatonin-mediated osteoblastogenesis and osteoclastogenesis using models that more closely mimics what occurs in vivo. Our central hypothesis is that melatonin, through MEK1/2 and 5, will stimulate osteoblastogenesis and inhibit osteoclastogenesis by modulating osteoblast-specific markers, RUNX2, osteocalcin and FRA-1 and by regulating the ratios of osteoprotegerin and RANKL to inhibit osteoclastogenesis, respectively. We plan to objectively test our hypothesis by pursuing the following two specific aims: (1) Assess the effects of MEK5 on melatonin-mediated osteoblast and osteoclast differentiation and signaling in hMSC-hPBMC co-cultures; (2) Assess the role of melatonin and MEK1/2 and 5 on melatonin-mediated changes in osteoblast and osteoclast function, bone formation and density in vivo. These studies will not only clarify the mechanisms underlying melatonin's actions on osteoblasts, osteoclasts and bone but will also identify a novel target (MEK5) for the development of future bone-forming therapies to reduce fracture risk in susceptible populations.
 描述(申请人提供):我们的长期目标是开发新的疗法,以改善骨形成和增加骨密度的女性和男性骨量减少或骨质疏松。褪黑素是当前治疗方法的一种新的替代品,因为它通过刺激成骨细胞、抑制破骨细胞以及可能通过其清除自由基的特性来保护骨细胞免受过度的骨吸收,从而具有多种骨保护作用。人们预计长期使用褪黑素将通过对成骨细胞和破骨细胞的作用来预防骨量减少和骨质疏松,并减少骨折。采用人骨髓间充质干细胞(HMSCs)与人外周血单核细胞(HPBMCs)共培养体系,探讨褪黑素对啮齿类动物成骨细胞和破骨细胞的作用机制(S)。该项目的目标是使用更接近体内发生的模型来确定MEK5和MEK1/2在调节褪黑素介导的成骨细胞生成和破骨细胞生成中的作用。我们的中心假设是褪黑素通过MEK1/2和5,分别通过调节成骨细胞特异性标志物RUNX2、Osteocalin和FRA-1,以及通过调节护骨素和RANKL的比例来抑制破骨细胞生成,从而刺激成骨细胞的生成和抑制破骨细胞的生成。我们计划通过追求以下两个特定目标来客观验证我们的假设:(1)评估MEK5对褪黑素介导的成骨细胞和破骨细胞分化和信号的影响;(2)评估褪黑素和MEK1/2和5在体内褪黑素介导的成骨细胞和破骨细胞功能、骨形成和密度变化中的作用。这些研究不仅将阐明褪黑素对成骨细胞、破骨细胞和骨骼的作用机制,还将为未来的骨形成疗法的开发确定一个新的靶点(MEK5),以降低易感人群的骨折风险。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PAULA ANN WITT-ENDERBY其他文献

PAULA ANN WITT-ENDERBY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PAULA ANN WITT-ENDERBY', 18)}}的其他基金

MECHANISMS UNDERLYING MELATONIN RECEPTOR FUNCTION
褪黑激素受体功能的机制
  • 批准号:
    2729010
  • 财政年份:
    1999
  • 资助金额:
    $ 36.4万
  • 项目类别:
MUSCARINIC RECEPTOR DESENSITIZATION BY PHOSPHORYLATION
通过磷酸化使毒蕈碱受体脱敏
  • 批准号:
    2213802
  • 财政年份:
    1995
  • 资助金额:
    $ 36.4万
  • 项目类别:
MUCARINIC RECEPTOR DESENSITIZATION BY PHOSPHORYLATION
通过磷酸化使毒蕈碱受体脱敏
  • 批准号:
    2213800
  • 财政年份:
    1994
  • 资助金额:
    $ 36.4万
  • 项目类别:
MUSCARINIC RECEPTOR DESENSITIZATION BY PHOSPHORYLATION
通过磷酸化使毒蕈碱受体脱敏
  • 批准号:
    2213801
  • 财政年份:
    1994
  • 资助金额:
    $ 36.4万
  • 项目类别:

相似海外基金

Interplay between Aging and Tubulin Posttranslational Modifications
衰老与微管蛋白翻译后修饰之间的相互作用
  • 批准号:
    24K18114
  • 财政年份:
    2024
  • 资助金额:
    $ 36.4万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The Canadian Brain Health and Cognitive Impairment in Aging Knowledge Mobilization Hub: Sharing Stories of Research
加拿大大脑健康和老龄化认知障碍知识动员中心:分享研究故事
  • 批准号:
    498288
  • 财政年份:
    2024
  • 资助金额:
    $ 36.4万
  • 项目类别:
    Operating Grants
EMNANDI: Advanced Characterisation and Aging of Compostable Bioplastics for Automotive Applications
EMNANDI:汽车应用可堆肥生物塑料的高级表征和老化
  • 批准号:
    10089306
  • 财政年份:
    2024
  • 资助金额:
    $ 36.4万
  • 项目类别:
    Collaborative R&D
関節リウマチ患者のSuccessful Agingに向けたフレイル予防対策の構築
类风湿性关节炎患者成功老龄化的衰弱预防措施的建立
  • 批准号:
    23K20339
  • 财政年份:
    2024
  • 资助金额:
    $ 36.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
  • 批准号:
    498310
  • 财政年份:
    2024
  • 资助金额:
    $ 36.4万
  • 项目类别:
    Operating Grants
Life course pathways in healthy aging and wellbeing
健康老龄化和福祉的生命历程路径
  • 批准号:
    2740736
  • 财政年份:
    2024
  • 资助金额:
    $ 36.4万
  • 项目类别:
    Studentship
I-Corps: Aging in Place with Artificial Intelligence-Powered Augmented Reality
I-Corps:利用人工智能驱动的增强现实实现原地老龄化
  • 批准号:
    2406592
  • 财政年份:
    2024
  • 资助金额:
    $ 36.4万
  • 项目类别:
    Standard Grant
NSF PRFB FY 2023: Connecting physiological and cellular aging to individual quality in a long-lived free-living mammal.
NSF PRFB 2023 财年:将生理和细胞衰老与长寿自由生活哺乳动物的个体质量联系起来。
  • 批准号:
    2305890
  • 财政年份:
    2024
  • 资助金额:
    $ 36.4万
  • 项目类别:
    Fellowship Award
虚弱高齢者のSuccessful Agingを支える地域課題分析指標と手法の確立
建立区域问题分析指标和方法,支持体弱老年人成功老龄化
  • 批准号:
    23K20355
  • 财政年份:
    2024
  • 资助金额:
    $ 36.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
「ケア期間」に着目したbiological aging指標の開発
开发聚焦“护理期”的生物衰老指数
  • 批准号:
    23K24782
  • 财政年份:
    2024
  • 资助金额:
    $ 36.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了